Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico
Lupus · 2023
DOI: 10.1177/09612033231151898 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Lupus, 2023. Verfasst von Ariana González-Meléndez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Lupus Erythematosus, Systemic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
To determine if SARS-CoV-2 mRNA vaccination has an impact on the clinical course of systemic lupus erythematosus (SLE).
Methods
Puerto Ricans with SLE who received mRNA COVID-19 vaccines were studied. Demographic parameters, clinical manifestations, disease activity (per Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), disease damage (per Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), emergency room visits, hospitalizations, and pharmacologic therapy were determined. Baseline variables (prior to vaccination) were compared between patients with and without exacerbation after SARS-CoV-2 vaccination. Among those with exacerbation, clinical outcomes were determined up to 1 year after vaccination.
Results
Of the entire cohort ( n = 247), 14 (5.7%) had post-vaccination exacerbations. Photosensitivity, oral ulcers, anti-Ro antibodies, higher SLEDAI score, and corticosteroids exposure were associated with post-vaccination flares. Among those with post-vaccination flares, 10 (71.4%) had major organ involvement. No significant differences were observed for mean SLEDAI scores, emergency room visits, hospitalizations, disease damage, and exposure to immunosuppressive drugs before and after SARS-CoV-2 mRNA vaccination. At 12 months of follow-up, all patients were fully controlled without evidence of active disease.
Conclusion
In our group of SLE patients, 5.7% had a disease flare after SARS-CoV-2 mRNA vaccination. Most had exacerbations involving major organs/systems. Mucocutaneous manifestations, anti-Ro antibodies, disease activity, and corticosteroids were associated with flares. Awareness of these factors and the possibility of a major lupus flare after vaccination with COVD-19 vaccines is critical to provide timely and effective therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
- Department of Medicine, Universidad Central Del Caribe, Bayamón, Puerto Rico.
ORCID-Profile: Ariana González-Meléndez
Zitieren
APA
González-Meléndez, A., Báez-Negrón, L., Ríos-Rivera, R., Franco-O'Connell, A. S., Nieves-Plaza, M., & Vilá, L. M. (2023). Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico. Lupus. https://doi.org/10.1177/09612033231151898
Vancouver
González-Meléndez A, Báez-Negrón L, Ríos-Rivera R, Franco-O'Connell AS, Nieves-Plaza M, Vilá LM. Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico. Lupus. 2023. doi:10.1177/09612033231151898
BibTeX
@article{GonzlezMelndez2023,
author = {González-Meléndez, Ariana and Báez-Negrón, Laisha and Ríos-Rivera, Rafael and Franco-O'Connell, Alexandra S and Nieves-Plaza, Mariely and Vilá, Luis M},
title = {Short- and mid-term outcomes in systemic lupus erythematosus patients presenting with disease exacerbation after SARS-CoV-2 mRNA vaccination: A cohort study from Puerto Rico},
journal = {Lupus},
year = {2023},
doi = {10.1177/09612033231151898}
}
EUVIMED